Evaluating CV safety and potential for CV risk reduction with newer T2D agents
A slide lecture program on glucose lowering agents on CV risk, like: DPP4 inhibitors, GLP1 agonists, SGLT2 inhibitors
Developed and provided by the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS), an initiative from Boehringer Ingelheim & Lilly and published as an educational service with permission at PACE-CME,
Developed and provided by the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS), an initiative from Boehringer Ingelheim & Lilly and published as an educational service with permission at PACE-CME,
To download slides
Download PACE ACROSS T2D Module D_11Aug2015.pptx
To view slides clck on images
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
Share this page with your colleagues and friends: